Literature DB >> 16188953

Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2x [(+)2-amino-4,5,6,7-tetrahydro-6-Lpropylamino-benzathiazole dihydrochloride].

R Danzeisen1, B Schwalenstoecker, F Gillardon, E Buerger, V Krzykalla, K Klinder, L Schild, B Hengerer, A C Ludolph, C Dorner-Ciossek, L Kussmaul.   

Abstract

Pramipexole has been shown to possess neuroprotective properties in vitro that are partly independent of its dopaminergic agonism. The site of neuroprotective action is still unknown. Using [(3)H]pramipexole, we show that the drug enters and accumulates in cells and mitochondria. Detoxification of reactive oxygen species (ROS) by pramipexole is shown in vitro and in vivo by evaluating mitochondrial ROS release and aconitase-2 activity, respectively. Pramipexole and its (+)-enantiomer SND919CL2X [low-affinity dopamine agonist; (+)2-amino-4,5,6,7-tetrahydro-6-l-propylamino-benzathiazole dihydrochloride] possess equipotent efficacy toward hydrogen peroxide and nitric oxide generated in vitro and inhibit cell death in glutathione-depleted neuroblastoma cells. IC(50) values ranged from 15 to 1000 microM, consistent with the reactivity of the respective radical and the compartmentalization of ROS generation and ROS detoxification. Finally, both compounds were tested in superoxide dismutase 1-G93A mice, a model of familial amyotrophic lateral sclerosis. SND919CL2X (100 mg/kg) prolongs survival time and preserves motor function in contrast to pramipexole (3 mg/kg), which shows an increase in running wheel activity before disease onset, presumably caused by the dopaminergic agonism. We conclude that both enantiomers, in addition to their dopaminergic activity, are able to confer neuroprotective effects by their ability to accumulate in brain, cells, and mitochondria where they detoxify ROS. However, a clinical use of pramipexole as a mitochondria-targeted antioxidant is unlikely, because the high doses needed for antioxidative action in vitro are not accessible in vivo due to dopaminergic side effects. In contrast, SND919CL2X may represent the prototype of a mitochondria-targeted neuroprotectant because it has the same antioxidative properties without causing adverse effects.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16188953     DOI: 10.1124/jpet.105.092312

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  30 in total

Review 1.  [Amyotrophic lateral sclerosis. Current clinical trials and underlying pathomechanisms].

Authors:  K Kollewe; R Dengler; S Petri
Journal:  Nervenarzt       Date:  2008-06       Impact factor: 1.214

Review 2.  Moving forward in clinical trials for ALS: motor neurons lead the way please.

Authors:  Bariş Genç; P Hande Özdinler
Journal:  Drug Discov Today       Date:  2013-10-27       Impact factor: 7.851

3.  Synergistic Interaction Between Zinc and Reactive Oxygen Species Amplifies Ischemic Brain Injury in Rats.

Authors:  Yongmei Zhao; Feng Yan; Jie Yin; Rong Pan; Wenjuan Shi; Zhifeng Qi; Yalan Fang; Yuyou Huang; Sen Li; Yumin Luo; Xunming Ji; Ke Jian Liu
Journal:  Stroke       Date:  2018-09       Impact factor: 7.914

4.  Effects of dexpramipexole on brain mitochondrial conductances and cellular bioenergetic efficiency.

Authors:  Kambiz N Alavian; Steven I Dworetzky; Laura Bonanni; Ping Zhang; Silvio Sacchetti; Maria A Mariggio; Marco Onofrj; Astrid Thomas; Hongmei Li; Jamie E Mangold; Armando P Signore; Ulrike Demarco; Damon R Demady; Panah Nabili; Emma Lazrove; Peter J S Smith; Valentin K Gribkoff; Elizabeth A Jonas
Journal:  Brain Res       Date:  2012-01-28       Impact factor: 3.252

5.  Ribonuclease 4 protects neuron degeneration by promoting angiogenesis, neurogenesis, and neuronal survival under stress.

Authors:  Shuping Li; Jinghao Sheng; Jamie K Hu; Wenhao Yu; Hiroko Kishikawa; Miaofen G Hu; Kaori Shima; David Wu; Zhengping Xu; Winnie Xin; Katherine B Sims; John E Landers; Robert H Brown; Guo-fu Hu
Journal:  Angiogenesis       Date:  2012-11-10       Impact factor: 9.596

6.  The abolishment of anesthesia-induced cognitive impairment by timely protection of mitochondria in the developing rat brain: the importance of free oxygen radicals and mitochondrial integrity.

Authors:  A Boscolo; J A Starr; V Sanchez; N Lunardi; M R DiGruccio; C Ori; A Erisir; P Trimmer; J Bennett; V Jevtovic-Todorovic
Journal:  Neurobiol Dis       Date:  2011-12-14       Impact factor: 5.996

7.  Safety and Tolerability of R(+) Pramipexole in Mild-to-Moderate Alzheimer's Disease.

Authors:  James Bennett; Jeffrey Burns; Paul Welch; Rebecca Bothwell
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

8.  Potential therapeutic drugs and methods for the treatment of amyotrophic lateral sclerosis.

Authors:  G Yacila; Y Sari
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

9.  Mitochondrial protectant pramipexole prevents sex-specific long-term cognitive impairment from early anaesthesia exposure in rats.

Authors:  A Boscolo; C Ori; J Bennett; B Wiltgen; V Jevtovic-Todorovic
Journal:  Br J Anaesth       Date:  2013-04-24       Impact factor: 9.166

10.  Mitochondria-targeted antioxidant effects of S(-) and R(+) pramipexole.

Authors:  Giulia Ferrari-Toninelli; Giuseppina Maccarinelli; Daniela Uberti; Erich Buerger; Maurizio Memo
Journal:  BMC Pharmacol       Date:  2010-02-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.